Merck KGaA pays $169M upfront in deal for Hengrui’s PARP1 inhibitorPARP1 inhibitor and ADC

30 Oct 2023
endpts.com
License out/inADC
Merck KGaA is spending €160 million ($169 million) upfront in a licensing and option agreement for a pair of oncology assets from Jiangsu Hengrui Pharmaceuticals — a PARP1 inhibitorPARP1 inhibitor and a Claudin-18.2 antibody-drug conjugate.
Merck KGaA will get ex-China rights to Hengrui’s PARP1 inhibitorPARP1 inhibitor, HRS-1167, as well as an option for ex-China rights to its ADC, SHR-A1904. The German major also has the option to co-promote both assets in China. Besides the upfront cash, Hengrui is eligible for up to €1.4 billion ($1.48 billion) in milestones as well as tiered royalties on net sales.
Merck KGaA pays $169M upfront in deal for Hengrui’s PARP1 inhibitor and ADC
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.